Development of pyrimidine-based inhibitors of Janus tyrosine kinase 3.

Article Details

Citation

Copy to clipboard

Chen JJ, Thakur KD, Clark MP, Laughlin SK, George KM, Bookland RG, Davis JR, Cabrera EJ, Easwaran V, De B, George Zhang Y

Development of pyrimidine-based inhibitors of Janus tyrosine kinase 3.

Bioorg Med Chem Lett. 2006 Nov 1;16(21):5633-8. Epub 2006 Aug 24.

PubMed ID

16934457 [ View in PubMed

]

Abstract

A new class of pyrimidine-based Janus tyrosine kinase 3 (JAK3) inhibitors are described. Many of these inhibitors showed low nanomolar activity against JAK3.

DrugBank Data that Cites this Article

Binding Properties

Drug	Target	Property	Measurement	pH	Temperature (°C)
Tofacitinib	Tyrosine-protein kinase JAK2	IC 50 (nM)	11	N/A	N/A	Details
Tofacitinib	Tyrosine-protein kinase JAK3	IC 50 (nM)	13	N/A	N/A	Details